## Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

|  | armaceuticals Inc                       |                |   |   |             |              |   |  |                                |  |  |
|--|---|----------------|---|---|-------------|--------------|---|--|--------------------------------|--|--|
| Form 4   |   |                |   |   |             |              |   |  |                                |  |  |
| April 18, 20   |   |                |   |   |             |              |   |  |                                |  |  |
| FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION  |   |                |   |   |             |              |   | т  | OMB APPROVAL                   |  |  |
| Washington, D.C. 20549   |   |                |   |   |             |              |   | OMB<br>Number:   | 3235-0287                      |  |  |
| Check this box<br>if no longer<br>subject to<br>Section 16.<br>Form 4 or<br>Form 5<br>obligations<br>may continue.<br>See Instruction<br>See Instruction<br>Section 17(a) of the Public Utility Holding Company Act of 1940<br>Section 17(a) of the Investment Company Act of 1940 |   |                |   |   |             |              | ange Act of 1934,<br>t of 1935 or Sectio                      | Estimated average<br>burden hours per<br>response 0.                 |                                |  |  |
| <i>See</i> Inst<br>1(b).   | ruction                                 | ( )            |   |   | · · ·       | <b>J</b>     |   |  |                                |  |  |
| (Print or Type<br>1. Name and<br>GREEN JC  | Address of Reporting                    |                | Symbol  | er Name <b>and</b>  |             | -            | 5. Relationship o<br>Issuer                                   | f Reporting Per  | rson(s) to                     |  |  |
|  |   |                | Dicerna Pharmaceuticals Inc<br>[DRNA]                   |   |             |              | (Check all applicable)  |  |                                |  |  |
|  |   | C., 87         |   | of Earliest Tr<br>Day/Year)<br>2016   | ransaction  |              | Director<br>X Officer (giv<br>below)<br>Chief                 |  | % Owner<br>her (specify<br>cer |  |  |
|  |   |                | 4. If Amendment, Date Original<br>Filed(Month/Day/Year) |   |             |              | 6. Individual or Joint/Group Filing(Check<br>Applicable Line) |  |                                |  |  |
| CAMBRIE  | OGE, MA 02140                           |                |   |   |             |              | _X_ Form filed by<br>Form filed by 1<br>Person                | One Reporting P<br>More than One R                                   |                                |  |  |
| (City)   | (State)                                 | (Zip)          | Tab   | le I - Non-I  | Derivative  | Securities A | Acquired, Disposed o  | of, or Beneficia   | lly Owned                      |  |  |
| 1.Title of<br>Security<br>(Instr. 3)   | 2. Transaction Date<br>(Month/Day/Year) |                |   | 3. 4. Securities<br>TransactionAcquired (A) or<br>Code Disposed of (D)<br>(Instr. 8) (Instr. 3, 4 and 5)<br>(A)<br>or |             |              | Securities<br>Beneficially<br>Owned                           | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I)<br>(Instr. 4) |                                |  |  |
|  |   |                |   | Code V  | Amount      | (D) Price    | (insu: 5 and 4)   |  |                                |  |  |
| Reminder: Re   | port on a separate line                 | e for each cla | ss of sec   | urities benef   | ficially ow | ned directly | or indirectly.  |  |                                |  |  |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2. 3. Transaction Date<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security |            | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | <ol> <li>5. Number of<br/>actionDerivative<br/>Securities</li> <li>8) Acquired (A) or<br/>Disposed of (D)<br/>(Instr. 3, 4, and<br/>5)</li> </ol> |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                            |  |  |
|--|---|------------|---|--|---|-----|--|--------------------|---|----------------------------|--|--|
|  |   |            |   | Code V                                 | (A)   | (D) | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>Number<br>Shares |  |  |
| Employee<br>Stock<br>Option<br>(Right to<br>Buy)   | \$ 5.45   | 04/14/2016 |   | A                                      | 265,000   |     | <u>(1)</u>   | 04/14/2026         | Common<br>Stock   | 265,00                     |  |  |
| Reporting Owners   |   |            |   |  |   |     |  |                    |   |                            |  |  |
| Reporting Owner Name / Address   |   |            |   | Relationships                          |   |     |  |                    |   |                            |  |  |
|  |   |            | Director  | 10% Owr                                | ner Officer   | r   |  | Other              |   |                            |  |  |
| GREEN JOHN B<br>C/O DICERNA PHARMACEUTICALS<br>87 CAMBRIDGEPARK DRIVE<br>CAMBRIDGE, MA 02140 |   |            | S, INC.   | Chief Financial Officer                |   |     |  |                    |   |                            |  |  |
| Signat   | ures  |            |   |  |   |     |  |                    |   |                            |  |  |
| /s/ Michael Todisco,<br>attorney-in-fact   |   |            | 04/18/2016  |  |   |     |  |                    |   |                            |  |  |

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The option vests 25% after the first year anniversary of the vesting start date of April 14, 2016 and the remaining 75% vests in 36

(1) substantially equal monthly installments thereafter, subject in each case to the reporting person's continued employment with the issuer through the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.